# Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

> **NCT03609216** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 237 (actual)

## Conditions studied

- Infiltrating Bladder Urothelial Carcinoma
- Stage II Bladder Urothelial Carcinoma
- Stage III Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Cisplatin
- **BIOLOGICAL:** Pegfilgrastim
- **PROCEDURE:** Conventional Surgery
- **PROCEDURE:** Radical Cystectomy
- **OTHER:** Chemoradiotherapy

## Key facts

- **NCT ID:** NCT03609216
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-10
- **Primary completion:** 2027-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609216, "Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03609216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*